…..then the combined minds of the National Institutes of Health, ten major drug companies, and seven nonprofit groups ought to be able to make some progress. This unique collaboration plans to target treatment development for lupus, rheumatoid arthritis, Alzheimer’s, and Type 2 diabetes over the next 5 years. The group were compelled to cooperation for different reasons: major drug companies have invested and lost in many promising treatments while other groups are inundated in biological data. Hopefully, by their powers combined, effective treatment option for these debilitating diseases.
(NIH Clinical Research Center from Wikicommons)
Read more about why these disorders were selected, the reasons for the joint effort, and more at the New York Times: http://www.nytimes.com/2014/02/05/health/nih-joins-drug-makers-and-nonprofits-on-stubborn-diseases.html?hp&_r=1.
